Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B

  • End date
    Dec 31, 2025
  • participants needed
  • sponsor
    Taichung Veterans General Hospital
Updated on 26 March 2022
antiviral therapy
antiviral agents


To compare the efficacy and renal safety of tenofovir alafenamide (TAF) versus entecavir (ETV) in the chronic hepatitis B patients.


With high antiviral potency and low drug resistance rate, both ETV and tenofovir disoproxil fumarate (TDF) have been recommended as the first-line antiviral therapy for chronic hepatitis B (CHB). However, risk of renal dysfunction remains an issue in TDF long-term therapy. Tenofovir alafenamide (TAF) is a novel prodrug of tenofovir and is formulated to deliver the active metabolite to target cells more efficiently than TDF at lower doses, thereby reducing systemic exposure to tenofovir. Importantly, TAF had improved renal safety as compared to TDF. TAF has been approved for treating CHB since 2017; however, it is still unknown whether the efficacy and renal safety of TAF is compatible to those of ETV. The investigators aim to conduct an open label, randomized controlled trial comparing TAF with ETV for assessing their efficacy and renal safety in CHB patients. The eligible CHB patients are randomly assigned (1:1) to receive TAF or ETV. After allocation to TAF group or ETV group, study subjects will receive therapy for 3 years (144 weeks).

Condition Hepatitis B, Viral Hepatitis
Treatment Entecavir, Tenofovir alafenamide
Clinical Study IdentifierNCT03933384
SponsorTaichung Veterans General Hospital
Last Modified on26 March 2022


Yes No Not Sure

Inclusion Criteria

Patients more than 20 years old
Chronic hepatitis B patients
Patients who were indicated for hepatitis B virus antiviral therapy

Exclusion Criteria

Decompensated liver disease (Child-Pugh B &C)
End stage renal disease (eGRF < 15 ml/min/1.73m2)
Prior use of nucleot(s)ide analogues for chronic hepatitis B
Prior use of interferon for chronic hepatitis B within six months
Known history of human immunodeficiency virus or hepatitis C virus co-infection
Concurrent other uncontrolled malignancy
Women in pregnancy or lactation
Cannot conform to the study protocol of this study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note